Sirio Pharma receives sports nutrition production licence approval
The approval enables Sirio to add special sports nutrition ingredients into products and covers six functional classes for ‘protein supplementary’, ‘speed & power’, ‘endurance’, ‘energy control’, ‘energy supplementary’, and ‘post-exercise recovery’.
Sirio Pharma – a global nutraceutical CDMO – has been granted SC (production licence) of sports nutrition food in China.
The approval enables Sirio to add special sports nutrition ingredients into products and covers six functional classes for ‘protein supplementary’, ‘speed & power’, ‘endurance’, ‘energy control’, ‘energy supplementary’, and ‘post-exercise recovery’. Due to the stringency of regulations and complexity of achieving approval, Sirio is now one of just seven approved licence holders in the country.
“In the last few years, sports nutrition in China has grown extremely quickly – at a CAGR of 37% between 2013 and 2017 – and is forecast to continue to expand at up to 50% per year, easily outstripping growth in the US and other global markets. So it is a huge opportunity not only for domestic companies, but also international brands,” commented Rui Yang, CSO of SIRIO Pharma.
Until recently, the barriers to entry for international brands in China were high, and the majority entered the market using cross-border e-commerce. However, Sirio’s new sports licence – coupled with its strong formulation capabilities and capacity – now provide the possibility of contract manufacturing these products in China and selling through all distribution channels across the country. Potentially opening-up a far larger customer base. It also enables international brands to start developing customized sports nutrition products that are tailored to local consumer preferences in China.
Significantly, the licence allows nutra brands to make specific functional claims on sports nutrition product labeling, and will cover popular ingredients including concentrated whey protein, whey protein isolate, soy protein isolate: BCAA, CaHMB, creatine, and many vitamin & minerals.
Yang added: “The consumer demand for sports products in China has exploded in the last few years, in part thanks to the national fitness policy, yet the production and regulatory environment is still maturing. As a result, only a very small number of companies have licences and, through Sirio, we foresee tremendous opportunities for brand companies to access one of the fastest growing segments of the nutrition industry globally. In fact, we have already had a number of enquiries and we are able to start production immediately. What is more, for established brands who want to build their name in the China, by partnering with Sirio, they are now even able to develop completely unique products tailored to the Chinese sports consumer.”
The new sports production licence has been introduced to better regulate manufacturers and combat counterfeit products in China, and involves a rigorous onsite audit covering environmental control, equipment, warehousing and documentation.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.